Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease?

被引:60
作者
Kienzl, E
Jellinger, K
Stachelberger, H
Linert, W
机构
[1] PKH, Ludwig Boltzmann Inst Clin Neurobiol, A-1140 Vienna, Austria
[2] Univ Technol, Inst Appl Bot Techn Microscopy & Organ Raw Mat St, Vienna, Austria
[3] Univ Technol, Inst Inorgan Chem, Vienna, Austria
关键词
iron; 6-hydroxydopamine; kinetics; nigrostriatal degeneration; substantia nigra;
D O I
10.1016/S0024-3205(99)00458-0
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The mechanisms leading to degeneration of melanized dopaminergic neurons in the brain stem, and particularly in the substantia nigra zona compacta (SNZC) in patients with Parkinson's disease (PD) are still unknown. Demonstration of increased iron Fe(III) in SNZC of PD brain has suggested that Fe-melanin interaction may contribute to oxidative neuronal damage. Energy dispersive X-ray electron microscopic analysis of the cellular distribution of trace elements revealed significant Fe-peaks, similar to those of a synthetic melanin-Fe(III) complex in intracytoplasmic electron-dense neuromelanin granules of SNZC neurons, with highest levels in a case of PD and Alzheimer's disease (AD). No Fe increase was found in Lewy bodies or in SN neurons of control specimens. The relevance of chemical reactions of dopamine (DA), 5-hydroxydopamine (5-OHDA), and 6-hydroxydopamine (6-OHDA) with Fe(III) and with dioxygen for the pathogenesis of PD was investigated. An initiating mechanism related to interaction between Fe and neuromelanin is suggested which results in accumulation of Fe(III) and a continuous production of cytotoxic species inducing a cascade of pathogenic reactions ultimately leading to neuronal death.
引用
收藏
页码:1973 / 1976
页数:4
相关论文
共 12 条
[1]   THE DETERMINATION OF HYDROXYDOPAMINES AND OTHER TRACE AMINES IN THE URINE OF PARKINSONIAN-PATIENTS AND NORMAL CONTROLS [J].
ANDREW, R ;
WATSON, DG ;
BEST, SA ;
MIDGLEY, JM ;
WENLONG, H ;
PETTY, RKH .
NEUROCHEMICAL RESEARCH, 1993, 18 (11) :1175-1177
[2]  
Arendash G. W., 1994, P175
[3]  
DEXTER DT, 1992, ANN NEUROL, V32, P94
[4]   PARKINSONISM - ONSET PROGRESSION AND MORTALITY [J].
HOEHN, MM ;
YAHR, MD .
NEUROLOGY, 1967, 17 (05) :427-&
[5]   IRON MELANIN COMPLEX IN SUBSTANTIA-NIGRA OF PARKINSONIAN BRAINS - AN X-RAY-MICROANALYSIS [J].
JELLINGER, K ;
KIENZL, E ;
RUMPELMAIR, G ;
RIEDERER, P ;
STACHELBERGER, H ;
BENSHACHAR, D ;
YOUDIM, MBH .
JOURNAL OF NEUROCHEMISTRY, 1992, 59 (03) :1168-1171
[6]  
JELLINGER K, 1993, IRON CENTRAL NERVOUS, P19
[7]   PATHOLOGY OF PARKINSONS-DISEASE - CHANGES OTHER THAN THE NIGROSTRIATAL PATHWAY [J].
JELLINGER, KA .
MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1991, 14 (03) :153-197
[8]   The role of transition metals in the pathogenesis of Parkinson's disease [J].
Kienzl, E ;
Puchinger, L ;
Jellinger, K ;
Linert, W ;
Stachelberger, H ;
Jameson, RF .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1995, 134 :69-78
[9]   Dopamine, 6-hydroxydopamine, iron, and dioxygen - Their mutual interactions and possible implication in the development of Parkinson's disease [J].
Linert, W ;
Herlinger, E ;
Jameson, RF ;
Kienzl, E ;
Jellinger, K ;
Youdim, MBH .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 1996, 1316 (03) :160-168
[10]  
OESTREICHER E, 1994, BRAIN RES, V600, P8